As-needed intranasal corticosteroid spray for allergic rhinitis: a systematic review and meta-analysis

Free Download

M.P. Hoang - W. Chitsuthipakorn - K. Seresirikachorn - K. Snidvongs

Background: As-needed intranasal corticosteroid spray (INCS) is commonly used by patients with allergic rhinitis (AR) who have suboptimal symptom control. This systematic review aimed to assess the effectiveness of as-needed INCS for treating AR.

Methodology: Systematic searches for randomized controlled trials studying the effects of as-needed INCS compared to regular INCS, as-needed antihistamine, or placebo were performed. Primary outcomes were total nasal symptom score (TNSS) and disease-specific quality of life (DSQoL).

Effect of momethasone furoate combined with loratadine and montelukast sodium on inflammatory factors and pulmonary function in children with allergic rhinitis

Am J Transl Res. 2022; 14(10): 7199–7207.

Weili Dai,1 Ni Zhen,2 Xiaoyan Qin,2 and Jingpeng Cao2

Abstract

Objective: To compare the effects of mometasone furoate in combination with loratadine and montelukast sodium on inflammatory factors and pulmonary function in children with allergic rhinitis (AR). Methods: In this retrospective study, a total of 89 children with AR admitted to our hospital from March 2020 to October 2021 were enrolled. Among them, 47 children who received mometasone furoate combined with loratadine were designated group A, while the other 42 with mometasone furoate combined with montelukast sodium were group B.

Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

Original Article - Open Access

Bernardo Sousa-Pinto,Aram Anto,Markus Berger,Stephanie Dramburg,Oliver Pfaar,Ludger Klimek,Marek Jutel,Wienczyslawa Czarlewski,Anna Bedbrook,Arunas Valiulis,Ioana Agache … See all authors

https://doi.org/10.1002/clt2.12208

Abstract

Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real-time, real-world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK-air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature.

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma

• Research
• Open Access
• 
  

• Linlin Ma, 
• Min Zhu, 
• Guanghui Li, 
• Junwei Gai, 
• Yanfei Li, 
• Huaiyu Gu, 
• Peng Qiao, 
• Xiaofei Li, 
• Weiwei Ji, 
• Rui Zhao, 
• Yue Wu & 
• Yakun Wan 

Respiratory Research volume 23, Article number: 316 (2022) 

Abstract

Background

Eosinophilic asthma is a common subtype of severe asthma with high morbidity and mortality. The cytokine IL-5 has been shown to be a key driver of the development and progression of disease. Although approved monoclonal antibodies (mAbs) targeting IL-5/IL-5R have shown good safety and efficacy, some patients have inadequate responses and frequent dosing results in medication nonadherence.

Impact of high-risk of obstructive sleep apnea on chronic cough: data from the Korea National Health and Nutrition Examination Survey

• Research
• Open Access
• 
  

• Tae Hoon Kim, 
• I Re Heo & 
• Ho Cheol Kim 

BMC Pulmonary Medicine volume 22, Article number: 419 (2022) 

• details

Abstract

Background

Chronic cough is an extremely common clinical symptom of various diseases. However, the relationship between obstructive sleep apnea (OSA) and chronic cough in the general population has not been sufficiently studied.

Methods

Using the 2019 Korean National Health and Nutrition Examination Survey data, we identified a group at high-risk of OSA via the STOP-Bang questionnaire and determined the association between OSA and chronic cough by a regression model.

Patients with allergic asthma have lower risk of severe COVID-19 outcomes than patients with nonallergic asthma

• Research
• Open Access
• 
  

• Thomas R. Murphy, 
• William Busse, 
• Cecile T. J. Holweg, 
• Yamina Rajput, 
• Karina Raimundo, 
• Craig S. Meyer, 
• Arpamas Seetasith, 
• Sachin Gupta, 
• Ahmar Iqbal & 
• Robert J. Kaner 

BMC Pulmonary Medicine volume 22, Article number: 418 (2022) 

• details

Abstract

Background

Although asthma does not appear to be a risk factor for severe coronavirus disease 2019 (COVID-19), outcomes could vary for patients with different asthma subtypes. The objective of this analysis was to compare COVID-19 outcomes in real-world cohorts in the United States among patients with asthma, with or without evidence of allergy.

Methods

In a retrospective analysis of the COVID-19 Optum electronic health record dataset (February 20, 2020–January 28, 2021), patients diagnosed with COVID-19 with a history of moderate-to-severe asthma were divided into 2 cohorts: those with evidence of allergic asthma and those without (nonallergic asthma).

Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms

Open Access

Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R, Acosta-Madiedo AS, Wen A, Moreno-López S, MacDonald M, Barrios M, Chu X, Islam N, Gao Y, Wong MM, Couban R, Garcia E, Chapman E, Oykhman P, Chen L, Winders T, Asiniwasis RN, Boguniewicz M, De Benedetto A, Ellison K, Frazier WT, Greenhawt M, Huynh J, Kim E, LeBovidge J, Lind ML, Lio P, Martin SA, O'Brien M, Ong PY, Silverberg JI, Spergel J, Wang J, Wheeler KE, Schneider L, Chu DK. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2022 Sep 30:S0091-6749(22)01322-7. doi: 10.1016/j.jaci.2022.09.020.

Abstract

Background: Atopic dermatitis (AD, eczema) is driven by a combination of skin barrier defects, immune dysregulation, and extrinsic stimuli such as allergens, irritants, and microbes. The role of environmental allergens (aeroallergens) in triggering AD remains unclear.

Temperature-controlled Laminar Airflow (TLA) in symptomatic severe asthma – a post hoc analysis of severe exacerbations, quality of life and health economics

• Research
• Open Access
• 
  

• A. J. Chauhan, 
• G. Eriksson, 
• W. Storrar, 
• T. Brown, 
• S. Peterson, 
• F. Radner, 
• L. G. D’Cruz, 
• P. Miller & 
• L. Bjermer 

BMC Pulmonary Medicine volume 22, Article number: 407 (2022) 

Abstract

Purpose

Uncontrolled severe asthma constitutes a major economic burden to society. Add-ons to standard inhaled treatments include inexpensive oral corticosteroids and expensive biologics. Nocturnal treatment with Temperature-controlled Laminar Airflow (TLA; Airsonett®) could be an effective, safe and cheaper alternative. The potential of TLA in reducing severe asthma exacerbations was addressed in a recent randomised placebo-controlled trial (RCT) in patients with severe asthma (Global Initiative for Asthma (GINA) step 4/5), but the results were inconclusive. We re-analysed the RCT with severe exacerbations stratified by the level of baseline asthma symptoms and Quality of Life.